Literature DB >> 8405016

Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.

M A Pue1, J Laroche, I Meineke, C de Mey.   

Abstract

The plasma pharmacokinetics of pantoprazole have been investigated following single intravenous infusion and single oral administration at a dose of 40 mg to 12 healthy male subjects in a randomised cross-over study. Both treatments were generally well tolerated and no relevant compound-related adverse events were noted. The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h. The apparent volume of distribution estimated at steady state (0.17 l.kg-1) was compatible with the localization of a major fraction of the compound in extracellular water. Following oral administration as an enteric-coated tablet formulation, a variable onset of absorption was followed by rapid attainment of maximum plasma concentrations of pantoprazole. Pantoprazole was well absorbed following oral administration; the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405016     DOI: 10.1007/bf02440862

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

Authors:  T Andersson; C Cederberg; G Edvardsson; A Heggelund; P Lundborg
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

2.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

3.  Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.

Authors:  B Simon; P Müller; H Bliesath; R Lühmann; M Hartmann; R Huber; W Wurst
Journal:  Aliment Pharmacol Ther       Date:  1990-06       Impact factor: 8.171

4.  The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.

Authors:  C G Regårdh; T Andersson; P O Lagerström; P Lundborg; I Skånberg
Journal:  Ther Drug Monit       Date:  1990-03       Impact factor: 3.681

5.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

6.  By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.

Authors:  W A Simon; D J Keeling; S M Laing; C Fallowfield; A G Taylor
Journal:  Biochem Pharmacol       Date:  1990-06-01       Impact factor: 5.858

7.  Oral pharmacokinetics of omeprazole.

Authors:  C W Howden; P A Meredith; J A Forrest; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  7 in total
  16 in total

1.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

Review 2.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 3.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

4.  Characterization of the ascending colon fluids in ulcerative colitis.

Authors:  Maria Vertzoni; Konstantinos Goumas; Erik Söderlind; Bertil Abrahamsson; Jennifer B Dressman; Androniki Poulou; Christos Reppas
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

5.  Erlotinib and pantoprazole: a relevant interaction or not?

Authors:  Rob Ter Heine; James C Fanggiday; Nienke A G Lankheet; Jos H Beijnen; Monique M L Van Der Westerlaken; Gerald H A Staaks; Mirte M Malingré
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

Review 6.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 7.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

8.  Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

Authors:  Kunihiro Suzuki; Kosuke Doki; Masato Homma; Hirofumi Tamaki; Satoko Hori; Hisakazu Ohtani; Yasufumi Sawada; Yukinao Kohda
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 9.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

10.  Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.

Authors:  David C Metz; Geraldine M Ferron; Jeffrey Paul; Mary Beth Turner; Elaine Soffer; Joseph R Pisegna; Wieslaw J Bochenek
Journal:  J Clin Pharmacol       Date:  2002-05       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.